FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly a pharmaceutical composition containing a somatostatin-dopamine conjugate which maintains activity both of somatostatin, and of dopamine in vivo. More specifically, the present invention refers to the pharmaceutical composition containing Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2 (SEQ ID NO:1) wherein the somatostatin-dopamine conjugate is deposited in vivo at physiological pH with sedimentation in situ which slowly dissociates and is released into body fluids and blood flow. The present invention may additionally contain an organic ingredient, such as dimethylacetamide (DMA) or polyethylene glycol of average molecular weight 400 (PEG400).
EFFECT: invention provides reducing side effects.
10 cl, 1 ex, 7 tbl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC EQUIVALENTS OF LIGANS OF SOMATOSTATIN AND DOPERMINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS BASED ON THEM AND MODALTIES OF SOMATOSTATIN AND/DOPERMINE RECEPTORS | 2004 |
|
RU2329273C2 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| CHIMERIC ANALOGS OF SOMATOSTATIN-DOPAMINE | 2002 |
|
RU2277539C2 |
| METHOD FOR MODULATING CELL PROLIFERATION OF THYROID MEDULLARY CARCINOMA | 2005 |
|
RU2317824C2 |
| METHOD OF MODULATION OF PROLIFERATION OF CELLS OF THYROID GLAND MEDULLARY CARCINOMA | 2002 |
|
RU2352578C2 |
| METHOD FOR MODULATING CELL PROLIFERATION OF MEDULLARY THYROID CARCINOMA | 2002 |
|
RU2275934C2 |
| CONJUGATES OF CYTOTOXIC AGENTS WITH PEPTIDES | 2007 |
|
RU2457218C2 |
| SOMATOSTATIN ANTAGONISTS | 2002 |
|
RU2263678C2 |
| SOMATOSTATIN AGONISTS | 2002 |
|
RU2259375C2 |
| SOMATOSTATIN ANTAGONISTS | 2002 |
|
RU2328504C2 |
